Insider Buying: ANIXA BIOSCIENCES INC (NASDAQ:ANIX) Director Buys 5,000 Shares of Stock

ANIXA BIOSCIENCES INC (NASDAQ:ANIX - Get Free Report) Director Arnold M. Baskies acquired 5,000 shares of the company's stock in a transaction dated Friday, July 18th. The shares were acquired at an average cost of $3.39 per share, with a total value of $16,950.00. Following the completion of the purchase, the director owned 125,000 shares in the company, valued at approximately $423,750. This represents a 4.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

ANIXA BIOSCIENCES Stock Performance

Shares of NASDAQ ANIX traded down $0.09 during midday trading on Tuesday, hitting $3.34. 135,150 shares of the company's stock traded hands, compared to its average volume of 106,208. The firm has a fifty day moving average of $3.07 and a 200 day moving average of $2.89. The stock has a market capitalization of $107.58 million, a price-to-earnings ratio of -8.79 and a beta of 0.39. ANIXA BIOSCIENCES INC has a 1 year low of $2.07 and a 1 year high of $4.20.

ANIXA BIOSCIENCES (NASDAQ:ANIX - Get Free Report) last released its earnings results on Tuesday, June 3rd. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. On average, equities analysts anticipate that ANIXA BIOSCIENCES INC will post -0.41 earnings per share for the current year.

Institutional Investors Weigh In On ANIXA BIOSCIENCES

Hedge funds have recently bought and sold shares of the stock. Private Advisor Group LLC acquired a new position in ANIXA BIOSCIENCES during the first quarter worth $35,000. Millennium Management LLC purchased a new stake in ANIXA BIOSCIENCES during the fourth quarter valued at about $26,000. Focus Partners Wealth purchased a new stake in ANIXA BIOSCIENCES during the fourth quarter valued at about $162,000. Jane Street Group LLC purchased a new stake in shares of ANIXA BIOSCIENCES in the fourth quarter worth about $67,000. Finally, Renaissance Technologies LLC lifted its stake in shares of ANIXA BIOSCIENCES by 36.5% in the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock worth $34,000 after acquiring an additional 3,900 shares in the last quarter. Institutional investors and hedge funds own 29.13% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on ANIX shares. HC Wainwright restated a "buy" rating and set a $7.00 target price on shares of ANIXA BIOSCIENCES in a research note on Tuesday, March 25th. Wall Street Zen raised ANIXA BIOSCIENCES from a "sell" rating to a "hold" rating in a report on Friday, June 6th. Finally, D. Boral Capital restated a "buy" rating and issued a $10.00 price target on shares of ANIXA BIOSCIENCES in a research report on Tuesday, June 10th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, ANIXA BIOSCIENCES has a consensus rating of "Buy" and an average target price of $9.00.

ANIXA BIOSCIENCES Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.